Xueyan Zhang
2PUBLICATIONS
1CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (2)
Sort by Publication Date:
|May 12, 2021
Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.Changhui Li, Wei Nie, Jingdong Guo
|Jul 02, 2020
Expression Level of Wnt5a Was Related to the Therapeutic Effects of First-Generation EGFR-TKIs.Hai Zhang, Xiaohua Yang, Fang Hu
Pageof 1
